Tak 003 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Tak 003. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Tak 003 Today - Breaking & Trending Today

Japan's Takeda in talks to bring novel dengue vaccine to India

Takeda is in talks with the Indian drug regulator to seek approval for its dengue vaccine, which has been shown to prevent hospitalizations in 83.6% of trial participants and 62% reduction in dengue illness ....

Takeda Pharmaceutical , Dengue Vaccine , Tak 003 , Simon Gallagher , Vector Borne Disease , Us Food And Drug Administration ,

Takeda and IDT Support Manufacturing of Johnson & Johnson's COVID-19 Vaccine


Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine
Monday, March 15, 2021 5:35PM IST (12:05PM GMT)
− Takeda will make manufacturing capacity available at IDT’s facilities in Germany
 
Takeda Pharmaceutical Company Limited
(TSE:4502/NYSE:TAK) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development and manufacturing organization, to utilize capacity at IDT previously reserved for Takeda’s dengue vaccine candidate (TAK-003) to manufacture the single-shot COVID-19 vaccine developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. At the end of a three-month period, the capacity will be returned to Takeda to resume critical manufacturing for the planned launch of its dengue vaccine, subject to regulatory approvals. ....

United States , Rachel Wiese , Kazumi Kobayashi , Biologika Gmb , Rajeev Venkayya , Plasma Alliance , Takeda Pharmaceutical Company Limited , German Center , Janssen Pharmaceutical Companies Of Johnson , Care Alliance , Takeda Pharmaceutical Company , Exchange Commission , Covid Rd Alliance , Government Of Japan Ministry Health Labour , Vaccine Research , Pharmaceutical Company Limited , Janssen Pharmaceutical Companies , Global Vaccine Business Unit , Health Labour , Rare Genetic , Plasma Derived Therapies , Annual Report , Media Contact , Outside Japan , Takeda Pharmaceutical , Idt Biologika Gmbh ,

Takeda's Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next Decade1


Takeda Pharmaceutical Company Limited
Takeda’s Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next Decade1
Friday, March 12, 2021 11:40AM IST (6:10AM GMT)
 
Aiming for Revenues of JPY 1 Trillion (approximately US$9 Billion2) by FY2030
Double-Digit Revenue Growth Expected to be Driven by a Balanced and Focused Geographic Presence, Portfolio of 14 Global Brands and Wave 1 Pipeline Assets
Commitment to Patient Access to Medicines and Addressing Unmet Patient Needs in Emerging Markets Underpin Sustainable Growth
 
(TSE:4502/NYSE:TAK) (“Takeda”) today outlined its ambition for above-market, double-digit revenue growth of its Growth and Emerging Markets Business Unit (“GEM BU”). The revenue goal of JPY 1 trillion (approximately US$9 billion) by FY2030 represents more than doubling of current revenues in GEM BU. This potential growth will be primarily driven by a balanced geographical focus and targ ....

United Arab Emirates , United States , Buenos Aires , Distrito Federal , Holly Campbell , Kazumi Kobayashi , Ricardo Marek , Asia Pacific , Exchange Commission , Takeda Pharmaceutical Company Limited , Takeda Pharmaceutical Company , Digit Revenue Growth Expected , Focused Geographic Presence , Patient Access , Addressing Unmet Patient Needs , Emerging Markets Underpin Sustainable , Pharmaceutical Company Limited , Emerging Markets Business Unit , Emerging Markets , Costa Saroukos , Rare Genetic , Plasma Derived Therapies , Emerging Markets Business , South America , Middle East , Annual Report ,